Earlier Biologic Use, Better Pediatric AD Control: Advancing Shared Decision-Making for Enhanced Long-Term Outcomes

This enduring dialogue discussion between two experts in treating atopic dermatitis incorporates the patient experience and aims to improve clinicians competence in optimizing biologic treatment for pediatric patients with moderate-to-severe atopic dermatitis. As a result of this educational activity, learners will be better able to: 1. Identify the need for systemic therapy among pediatric patients with moderate-to-severe AD; 2. Recognize pediatric patients with moderate-to-severe AD for whom biologic therapy is an appropriate, evidence-based option; 3. Review shared decision-making considerations regarding biologic therapy for pediatric patients with moderate-to-severe AD; and, 4. Integrate strategies to optimize biologic treatment for pediatric patients with moderate-to-severe AD. Learners have access to downloadable materials for use in future practice.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Cross-Specialty

Communication & Shared Decision-Making

Pricing

Free

Reported to ACCME by the provider

Microlearning
Credit · Up to 0.5 credits
Commercial Support

Released

Jul 29, 2026
Last day to claim credit

Jul 29, 2027 10 months left

Earlier Biologic Use, Better Pediatric AD Control: Advancing Shared Decision-Making for Enhanced Long-Term Outcomes

Related courses

More from Answers in CME Inc. (AiCME)